the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Big Pharma Embraces Pharmacogenomics - But Are We There Yet?

Published by Decision Resources, Inc. Contact us : +1-860-674-8796
Published 2006/08 Content info 31 Pages
Product code DR44368
Price From  US $ 1112 Order/Price list
US $ 1112 PDF by E-mail (Single User License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

  • Contents
  • Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
  • Pharmacogenomics in Practice
  • Leaders in the Implementation of PGx
  • Celera Genomics
  • Illumina
  • Perlegen Sciences
  • Well-Documented Patient Data Are Paramount
  • DeCode Genetics-Icelandic Population
  • Spectrum Expert Commentary: Difficulties in Using Founder Populations
  • The Mayo Clinic-Olmsted County Epidemiology Data
  • Genizon-Quebec French Canadian Founder Population
  • Industry's Current Use of Pharmacogenomics
  • Preclinical Drug Development
  • DeCode Genetics-Identifying New Drug Targets
  • Improving Safety and Efficacy of New Drugs
  • Patient Segmentation
  • Genentech/Roche/Chugai's Trastuzumab (Herceptin)
  • Clinical Data/Genaissance's Vilazodone
  • Perlegen's MCC-555
  • Encode's Information-Rich Clinical Trials
  • Drug Dosing and Metabolism
  • NeoPharm's LE-SN38
  • Warfarin (Bristol-Myers Squibb's Coumadin)
  • Azathioprine and Mercaptopurines
  • Adverse Drug Reactions
  • GlaxoSmithKline's Abacavir (Ziagen)
  • Eli Lilly's Atomoxetine (Strattera)
  • Post-Marketing Efficacy Issues
  • Epidermal Growth Factor Receptor-Based Drugs
  • Clinical Data and Genaissance's STRENGTH and CARING Studies
  • Major Challenges
  • Regulatory Issues
  • Reimbursement, Ethical, and Legal Issues
  • Spectrum Expert Commentary: FDA Establishes New Processes:
  • Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway
  • Outlook

Tables

  • 1. Financial Position of Key PGx Leaders, FY05
  • 2. Select Celera Collaborations
  • 3. Disease Correlations Identified by Celera
  • 4. Select Perlegen Collaborations
  • 5. Populations for Disease Correlation and PGx Studies
  • 6. Effect of Genotype on Drug-Drug Interactions
    • A. Examples of Different Categories of Biomarkers
  • 7. Select PGx Diagnostics

Figures

  • 1. Potential of PGx in Practice
  • 2. Founder Populations
  • 3. Genomewide Scans and SNP Mapping
  • 4. Genome-Based Drug Doses for Antidepressants
  • 5. UGT1A1 Genotype Testing Before Irinotecan Rx
    • A. Drug-Test Codevelopment Process
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.